A Blinded, Placebo-Controlled, Randomized, Single Ascending Dose Study in Healthy Male Subjects to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-37822681

Completed

• Conditions: psychosis; 10039628

• Registration Number: NL-OMON30850
• Lead Sponsor: Johnson & Johnson Pharmaceutical

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

healthy male subjects between 18 - 55 years of age
BMI between 18 and 30 kg/m²

Exclusion Criteria

History of, or currently active, significant illness or medical disorder
History of epilepsy or fits or unexplained black-outs
Significant history of or current neurological disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>safety and tolerability, adverse events, changes in blood pressure, pulse rate,<br /><br>lab. safety data, 12-lead ECG and physical examination.<br /><br>pharmacokinetic blood and urine tests<br /><br>pharmacodynamic evaluations: prolactine concentration, adaptive tracking,<br /><br>Saccadic eye movements, smooth pursuit eye movement test, Bond and Lader VAS,<br /><br>Bowden VAS, body sway, tapping, and pEEG.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N/A</p><br>